Pomalidomide Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-analysis of Phase II and Phase III Clinical Trials
ConclusionThree drug Pom-regimens yielded double the response rates when compared with Pom-LoDex (pooled ORR 61.9% vs 35.7%), with Bort-Pom-LoDex and CFZ-Pom-LoDex demonstrating better outcomes than others.Graphical abstract
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Leukemia | Lymphoma | Myeloma | Pneumonia | Statistics | Study | Thrombocytopenia | Treanda